ViaCyte is a regenerative medicine company focused on developing a transformative cell replacement therapy to free people with insulin-requiring diabetes from painful and frequent insulin injections, strict diet regimens, constant blood sugar monitoring, and serious chronic health conditions associated with the disease.

ViaCyte's innovative product is based on the differentiation of stem cells into pancreatic beta cell precursors with subcutaneous implantation in a retrievable and immune-protective encapsulation medical device. Once implanted, the precursor cells mature into endocrine cells that secrete insulin and other hormones in a regulated manner to control blood glucose levels.

San Diego, US
Size (employees)
63 (est)-4%
ViaCyte was founded in 1999 and is headquartered in San Diego, US
Report incorrect company information

ViaCyte Office Locations

ViaCyte has an office in San Diego
San Diego, US (HQ)
3550 General Atomics Ct
Show all (1)
Report incorrect company information

ViaCyte Financials and Metrics

Summary Metrics

Founding Date


ViaCyte total Funding

$94.9 m

ViaCyte latest funding size

$10 m

Time since last funding

a year ago

ViaCyte investors

ViaCyte's latest funding round in May 2017 was reported to be $10 m. In total, ViaCyte has raised $94.9 m
Show all financial metrics
Report incorrect company information

ViaCyte Online and Social Media Presence

Embed Graph
Report incorrect company information

ViaCyte News and Updates

Two-year Data from ViaCyte's STEP ONE Clinical Trial Presented at ADA 2018

SAN DIEGO, June 23, 2018 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced two-year data from Cohort 1 of the ongoing Safety, Tolerability, and Efficacy of VC-01™ (PEC-Encap™) Product Candidate in Type One Diabetes (STEP ONE) clinical trial....
Report incorrect company information

ViaCyte Company Life and Culture

Report incorrect company information